APO Research
Talk to an analyst

APO RESEARCH · REPORT

Irritable Bowel Syndrome Treatment Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Irritable Bowel Syndrome Treatment Drug Market Analysis and Forecast 2026-2032

21 December 2025192 pages

Choose your research edition.

Industry ResearchIrritable Bowel Syndrome Treatment Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Irritable Bowel Syndrome Treatment Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Irritable Bowel Syndrome Treatment Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Irritable Bowel Syndrome Treatment Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Irritable Bowel Syndrome Treatment Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Irritable Bowel Syndrome Treatment Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Irritable Bowel Syndrome Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Irritable Bowel Syndrome Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Irritable Bowel Syndrome Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Irritable Bowel Syndrome Treatment Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Irritable Bowel Syndrome Treatment Drug include Takeda Pharmaceutical Ltd, Johnson & Johnson, Roche, Pfizer Inc., Biogen, Abbvie Inc., AstraZeneca, Prometheus Laboratories Inc. (Nestle) and Bristol Myers Squibb, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Irritable Bowel Syndrome Treatment Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Irritable Bowel Syndrome Treatment Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome Treatment Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Irritable Bowel Syndrome Treatment Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Irritable Bowel Syndrome Treatment Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Irritable Bowel Syndrome Treatment Drug revenue, projected growth trends, production technology, application and end-user industry.

Irritable Bowel Syndrome Treatment Drug Segment by Company

Takeda Pharmaceutical Ltd

Johnson & Johnson

Roche

Pfizer Inc.

Biogen

Abbvie Inc.

AstraZeneca

Prometheus Laboratories Inc. (Nestle)

Bristol Myers Squibb

Bausch Health

Irritable Bowel Syndrome Treatment Drug Segment by Type

Corticosteroids

Immunomodulators

Antibiotics

Amino Salicylates

Others

Irritable Bowel Syndrome Treatment Drug Segment by Application

Hospitals

Specialty Clinics

Other

Irritable Bowel Syndrome Treatment Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome Treatment Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Irritable Bowel Syndrome Treatment Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Irritable Bowel Syndrome Treatment Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Irritable Bowel Syndrome Treatment Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Irritable Bowel Syndrome Treatment Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Corticosteroids Major Player Table 3. Immunomodulators Major Player Table 4. Antibiotics Major Player Table 5. Amino Salicylates Major Player Table 6. Others Major Player Table 7. Global Irritable Bowel Syndrome Treatment Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Specialty Clinics Major Player Table 10. Other Major Player Table 11. Irritable Bowel Syndrome Treatment Drug Industry Trends Table 12. Irritable Bowel Syndrome Treatment Drug Industry Drivers Table 13. Irritable Bowel Syndrome Treatment Drug Industry Opportunities and Challenges Table 14. Irritable Bowel Syndrome Treatment Drug Industry Restraints Table 15. Global Irritable Bowel Syndrome Treatment Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Irritable Bowel Syndrome Treatment Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Irritable Bowel Syndrome Treatment Drug Market Share by Region (2021-2026) Table 18. Global Irritable Bowel Syndrome Treatment Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Irritable Bowel Syndrome Treatment Drug Market Share by Region (2027-2032) Table 20. Global Irritable Bowel Syndrome Treatment Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Players (2021-2026) Table 22. Global Irritable Bowel Syndrome Treatment Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Irritable Bowel Syndrome Treatment Drug Key Players Headquarters & Area Served Table 24. Global Irritable Bowel Syndrome Treatment Drug Players, Product Type & Application Table 25. Global Irritable Bowel Syndrome Treatment Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Irritable Bowel Syndrome Treatment Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Irritable Bowel Syndrome Treatment Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Type (2021-2026) Table 32. Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Type (2027-2032) Table 33. Global Irritable Bowel Syndrome Treatment Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Application (2021-2026) Table 37. Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Application (2027-2032) Table 38. Takeda Pharmaceutical Ltd Company Information Table 39. Takeda Pharmaceutical Ltd Business Overview Table 40. Takeda Pharmaceutical Ltd Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Takeda Pharmaceutical Ltd Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 42. Takeda Pharmaceutical Ltd Recent Development Table 43. Johnson & Johnson Company Information Table 44. Johnson & Johnson Business Overview Table 45. Johnson & Johnson Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Johnson & Johnson Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 47. Johnson & Johnson Recent Development Table 48. Roche Company Information Table 49. Roche Business Overview Table 50. Roche Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Roche Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 52. Roche Recent Development Table 53. Pfizer Inc. Company Information Table 54. Pfizer Inc. Business Overview Table 55. Pfizer Inc. Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Pfizer Inc. Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 57. Pfizer Inc. Recent Development Table 58. Biogen Company Information Table 59. Biogen Business Overview Table 60. Biogen Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Biogen Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 62. Biogen Recent Development Table 63. Abbvie Inc. Company Information Table 64. Abbvie Inc. Business Overview Table 65. Abbvie Inc. Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Abbvie Inc. Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 67. Abbvie Inc. Recent Development Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. AstraZeneca Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 72. AstraZeneca Recent Development Table 73. Prometheus Laboratories Inc. (Nestle) Company Information Table 74. Prometheus Laboratories Inc. (Nestle) Business Overview Table 75. Prometheus Laboratories Inc. (Nestle) Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Prometheus Laboratories Inc. (Nestle) Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 77. Prometheus Laboratories Inc. (Nestle) Recent Development Table 78. Bristol Myers Squibb Company Information Table 79. Bristol Myers Squibb Business Overview Table 80. Bristol Myers Squibb Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Bristol Myers Squibb Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 82. Bristol Myers Squibb Recent Development Table 83. Bausch Health Company Information Table 84. Bausch Health Business Overview Table 85. Bausch Health Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Bausch Health Irritable Bowel Syndrome Treatment Drug Product Portfolio Table 87. Bausch Health Recent Development Table 88. North America Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 89. North America Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 90. North America Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 91. North America Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 92. North America Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. North America Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 94. North America Irritable Bowel Syndrome Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 95. Europe Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 96. Europe Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 97. Europe Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 98. Europe Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 99. Europe Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Europe Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Irritable Bowel Syndrome Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 102. China Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 103. China Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 104. China Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 105. China Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 107. Asia Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 108. Asia Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 109. Asia Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Irritable Bowel Syndrome Treatment Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Asia Irritable Bowel Syndrome Treatment Drug Revenue by Region (US$ Million) & (2021-2026) Table 112. Asia Irritable Bowel Syndrome Treatment Drug Revenue by Region (US$ Million) & (2027-2032) Table 113. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026) & (US$ Million) Table 114. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032) & (US$ Million) Table 115. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026) & (US$ Million) Table 116. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032) & (US$ Million) Table 117. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021-2026) & (US$ Million) Table 119. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Country (US$ Million) & (2027-2032) Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Irritable Bowel Syndrome Treatment Drug Image Figure 2. Global Irritable Bowel Syndrome Treatment Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Irritable Bowel Syndrome Treatment Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Corticosteroids Image Figure 5. Immunomodulators Image Figure 6. Antibiotics Image Figure 7. Amino Salicylates Image Figure 8. Others Image Figure 9. Global Irritable Bowel Syndrome Treatment Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Irritable Bowel Syndrome Treatment Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Specialty Clinics Image Figure 13. Other Image Figure 14. Global Irritable Bowel Syndrome Treatment Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Irritable Bowel Syndrome Treatment Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Irritable Bowel Syndrome Treatment Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Irritable Bowel Syndrome Treatment Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032) Figure 27. North America Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032) Figure 28. North America Irritable Bowel Syndrome Treatment Drug Revenue Share by Country (2021-2032) Figure 29. United States Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032) Figure 34. Europe Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032) Figure 35. Europe Irritable Bowel Syndrome Treatment Drug Revenue Share by Country (2021-2032) Figure 36. Germany Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032) Figure 46. China Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032) Figure 47. Asia Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032) Figure 49. Asia Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032) Figure 50. Asia Irritable Bowel Syndrome Treatment Drug Revenue Share by Region (2021-2032) Figure 51. Japan Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Irritable Bowel Syndrome Treatment Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Irritable Bowel Syndrome Treatment Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Corticosteroids
  • Immunomodulators
  • Antibiotics
  • Amino Salicylates
  • Others
Applications
  • Hospitals
  • Specialty Clinics
  • Other
Companies covered
  • Takeda Pharmaceutical Ltd
  • Johnson & Johnson
  • Roche
  • Pfizer Inc.
  • Biogen
  • Abbvie Inc.
  • AstraZeneca
  • Prometheus Laboratories Inc. (Nestle)
  • Bristol Myers Squibb
  • Bausch Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Irritable Bowel Syndrome Treatment Drug Market by Type
  3. 1.2.1 Global Irritable Bowel Syndrome Treatment Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Corticosteroids
  5. 1.2.3 Immunomodulators
  6. 1.2.4 Antibiotics
  7. 1.2.5 Amino Salicylates
  8. 1.2.6 Others
  9. 1.3 Irritable Bowel Syndrome Treatment Drug Market by Application
  10. 1.3.1 Global Irritable Bowel Syndrome Treatment Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Specialty Clinics
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Irritable Bowel Syndrome Treatment Drug Market Dynamics
  1. 2.1 Irritable Bowel Syndrome Treatment Drug Industry Trends
  2. 2.2 Irritable Bowel Syndrome Treatment Drug Industry Drivers
  3. 2.3 Irritable Bowel Syndrome Treatment Drug Industry Opportunities and Challenges
  4. 2.4 Irritable Bowel Syndrome Treatment Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Irritable Bowel Syndrome Treatment Drug Market Perspective (2021-2032)
  2. 3.2 Global Irritable Bowel Syndrome Treatment Drug Growth Trends by Region
  3. 3.2.1 Global Irritable Bowel Syndrome Treatment Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Irritable Bowel Syndrome Treatment Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Irritable Bowel Syndrome Treatment Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Irritable Bowel Syndrome Treatment Drug Revenue by Players
  2. 4.1.1 Global Irritable Bowel Syndrome Treatment Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Irritable Bowel Syndrome Treatment Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Irritable Bowel Syndrome Treatment Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Irritable Bowel Syndrome Treatment Drug Key Players Headquarters & Area Served
  7. 4.4 Global Irritable Bowel Syndrome Treatment Drug Players, Product Type & Application
  8. 4.5 Global Irritable Bowel Syndrome Treatment Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Irritable Bowel Syndrome Treatment Drug Market CR5 and HHI
  11. 4.6.3 2025 Irritable Bowel Syndrome Treatment Drug Tier 1, Tier 2, and Tier 3
5 Irritable Bowel Syndrome Treatment Drug Market Size by Type
  1. 5.1 Global Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2032)
  3. 5.3 Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Type (2021-2032)
6 Irritable Bowel Syndrome Treatment Drug Market Size by Application
  1. 6.1 Global Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2032)
  3. 6.3 Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Ltd
  2. 7.1.1 Takeda Pharmaceutical Ltd Company Information
  3. 7.1.2 Takeda Pharmaceutical Ltd Business Overview
  4. 7.1.3 Takeda Pharmaceutical Ltd Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Ltd Irritable Bowel Syndrome Treatment Drug Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Ltd Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Irritable Bowel Syndrome Treatment Drug Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Roche
  14. 7.3.1 Roche Company Information
  15. 7.3.2 Roche Business Overview
  16. 7.3.3 Roche Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Roche Irritable Bowel Syndrome Treatment Drug Product Portfolio
  18. 7.3.5 Roche Recent Developments
  19. 7.4 Pfizer Inc.
  20. 7.4.1 Pfizer Inc. Company Information
  21. 7.4.2 Pfizer Inc. Business Overview
  22. 7.4.3 Pfizer Inc. Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc. Irritable Bowel Syndrome Treatment Drug Product Portfolio
  24. 7.4.5 Pfizer Inc. Recent Developments
  25. 7.5 Biogen
  26. 7.5.1 Biogen Company Information
  27. 7.5.2 Biogen Business Overview
  28. 7.5.3 Biogen Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Biogen Irritable Bowel Syndrome Treatment Drug Product Portfolio
  30. 7.5.5 Biogen Recent Developments
  31. 7.6 Abbvie Inc.
  32. 7.6.1 Abbvie Inc. Company Information
  33. 7.6.2 Abbvie Inc. Business Overview
  34. 7.6.3 Abbvie Inc. Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Abbvie Inc. Irritable Bowel Syndrome Treatment Drug Product Portfolio
  36. 7.6.5 Abbvie Inc. Recent Developments
  37. 7.7 AstraZeneca
  38. 7.7.1 AstraZeneca Company Information
  39. 7.7.2 AstraZeneca Business Overview
  40. 7.7.3 AstraZeneca Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AstraZeneca Irritable Bowel Syndrome Treatment Drug Product Portfolio
  42. 7.7.5 AstraZeneca Recent Developments
  43. 7.8 Prometheus Laboratories Inc. (Nestle)
  44. 7.8.1 Prometheus Laboratories Inc. (Nestle) Company Information
  45. 7.8.2 Prometheus Laboratories Inc. (Nestle) Business Overview
  46. 7.8.3 Prometheus Laboratories Inc. (Nestle) Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Prometheus Laboratories Inc. (Nestle) Irritable Bowel Syndrome Treatment Drug Product Portfolio
  48. 7.8.5 Prometheus Laboratories Inc. (Nestle) Recent Developments
  49. 7.9 Bristol Myers Squibb
  50. 7.9.1 Bristol Myers Squibb Company Information
  51. 7.9.2 Bristol Myers Squibb Business Overview
  52. 7.9.3 Bristol Myers Squibb Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bristol Myers Squibb Irritable Bowel Syndrome Treatment Drug Product Portfolio
  54. 7.9.5 Bristol Myers Squibb Recent Developments
  55. 7.10 Bausch Health
  56. 7.10.1 Bausch Health Company Information
  57. 7.10.2 Bausch Health Business Overview
  58. 7.10.3 Bausch Health Irritable Bowel Syndrome Treatment Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bausch Health Irritable Bowel Syndrome Treatment Drug Product Portfolio
  60. 7.10.5 Bausch Health Recent Developments
8 North America
  1. 8.1 North America Irritable Bowel Syndrome Treatment Drug Revenue (2021-2032)
  2. 8.2 North America Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032)
  5. 8.3 North America Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032)
  9. 8.5 North America Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Irritable Bowel Syndrome Treatment Drug Revenue by Country
  11. 8.6.1 North America Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Irritable Bowel Syndrome Treatment Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Irritable Bowel Syndrome Treatment Drug Revenue (2021-2032)
  2. 9.2 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Country
  11. 9.6.1 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Irritable Bowel Syndrome Treatment Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Irritable Bowel Syndrome Treatment Drug Revenue (2021-2032)
  2. 10.2 China Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032)
  5. 10.3 China Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032)
  9. 10.5 China Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Irritable Bowel Syndrome Treatment Drug Revenue (2021-2032)
  2. 11.2 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Country
  11. 11.6.1 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Irritable Bowel Syndrome Treatment Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue (2021-2032)
  2. 12.2 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Country
  11. 12.6.1 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Irritable Bowel Syndrome Treatment Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst